EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A neuraminidase-targeted nanobody confers broad protection against influenza B virus

Hang Jia, Chaohui Lin, Yinghao Guo, Weigang Cai, Renfang Guan, Lizhu Zhu, Qian Yang, Huihui Kong iD, Bin Sun iD, Zeli Zhang iD, Jian Ma iD

Journal of Virology · 18.08.2026 · 100 (8)

DOI: 10.1128/jvi.00762-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, erschienen am 18.08.2026. Verfasst von Hang Jia und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreatobiliary Surgery and Department of Immunology, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical Univ…. Hauptthemen laut MEDLINE: Influenza B virus, Neuraminidase, Single-Domain Antibodies, Orthomyxoviridae Infections. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Key Research and Development Program of China, Natural Science Foundation for Young Scientists of Shanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Influenza B virus (IBV) exhibits antigenic diversity and significantly contributes to the annual burden of influenza-related disease, posing substantial impacts on global public health and the economy. In this study, we focused on the neuraminidase (NA) of IBV, immunized an alpaca with tetrameric IBV NA, and identified a series of nanobodies with a common feature of the “DYR” motif in CDR3, exhibiting broad inhibitory activity against diverse NAs of IBV. Among these, the most potent VHH5 broadly inhibits NA from multiple representative strains across ancestral, B/Yamagata/16/88-like, and B/Victoria/2/87-like lineages. Moreover, fusing VHH5 to a human immunoglobulin G1 Fc domain significantly increased its antiviral potency in vitro , with the 50% inhibitory concentration in the low nanomolar range. Structural modeling and molecular dynamics simulations revealed that the “DYR” motif within the elongated CDR3 loop of VHH5 penetrates the catalytic pocket and engages the highly conserved catalytic site of IBV NA. Experimental mutagenesis analysis of the predicted interface further supported this binding model. Furthermore, the VHH5-Fc protects mice from the lethal challenge with a high dose of the IBV-2024 virus in both prophylactic and therapeutic settings. Our findings highlight the potential of the Fc-fused VHH5 antibody in controlling influenza B virus infections. IMPORTANCE Although influenza B viruses (IBVs) account for a substantial proportion of seasonal influenza virus infections, they have received comparatively less research attention. The small size and flexible binding modes of nanobodies enable them to access cryptic or recessed epitopes, supporting their development as potent clinical therapeutics. Here, we report the identification of VHH5, a nanobody targeting conserved residues within the neuraminidase active site of the influenza B virus, conferring broad inhibitory activity. Moreover, Fc-fused VHH5 enhanced antiviral potency in vitro and provided robust protection against lethal IBV challenge in mice. Together, these findings establish VHH5-Fc as a promising therapeutic candidate with potent and broad-spectrum activity against antigenically diverse IBV strains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza B virusNeuraminidaseSingle-Domain AntibodiesOrthomyxoviridae InfectionsViral ProteinsAnimalsHumansCamelids, New WorldAntibodies, ViralDogsMiceMolecular Dynamics SimulationFemale

Stichwörter der Autor:innen

antiviral therapyenzymatic inhibitioninfluenza B virusnanobodyneuraminidase

Substanzen

NeuraminidaseSingle-Domain AntibodiesAntibodies, ViralViral Proteins

Autor:innen und Institutionen

  • Department of Pancreatobiliary Surgery and Department of Immunology, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, China.
  • Zhejiang Key Laboratory of Multi-Omics in Infection and Immunity, Center for Infectious Disease Research, School of Medicine, Westlake University, Hangzhou, China.
  • Worldwide Influenza Centre, The Francis Crick Institute, London, United Kingdom.
  • State Key Laboratory of Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.
  • Research Center for Pharmacoinformatics, College of Pharmacy, Harbin Medical University, Harbin, China.

ORCID-Profile: Huihui Kong, Bin Sun, Zeli Zhang, Jian Ma

Förderung

  • The National Key Research and Development Program of China
  • Natural Science Foundation for Young Scientists of Shanxi Province

Zitieren

APA

Jia, H., Lin, C., Guo, Y., Cai, W., Guan, R., Zhu, L., Yang, Q., Kong, H., Sun, B., Zhang, Z., & Ma, J. (2026). A neuraminidase-targeted nanobody confers broad protection against influenza B virus. Journal of Virology, 100(8). https://doi.org/10.1128/jvi.00762-26

Vancouver

Jia H, Lin C, Guo Y, Cai W, Guan R, Zhu L, et al. A neuraminidase-targeted nanobody confers broad protection against influenza B virus. Journal of Virology. 2026;100(8). doi:10.1128/jvi.00762-26

BibTeX
@article{Jia2026,
  author = {Jia, Hang and Lin, Chaohui and Guo, Yinghao and Cai, Weigang and Guan, Renfang and Zhu, Lizhu and Yang, Qian and Kong, Huihui and Sun, Bin and Zhang, Zeli and Ma, Jian},
  title = {A neuraminidase-targeted nanobody confers broad protection against influenza B virus},
  journal = {Journal of Virology},
  year = {2026},
  volume = {100},
  number = {8},
  doi = {10.1128/jvi.00762-26}
}
Kostenlos starten →